Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.57 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 15/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073751 | 0.85 | EDNRA (0.58) | EDNRAKMT2A | |
| SCHEMBL8054308 | 0.84 | EDNRA (0.57) | EDNRAKMT2A | |
| SCHEMBL2372669 | 0.84 | EDNRA (0.57) | EDNRAUSP30KMT2A | |
| SCHEMBL11066209 | 0.82 | KMT2A (0.42) | NSD2EDNRAUSP30KMT2A | |
| SCHEMBL15461567 | 0.81 | EDNRA (0.54) | EDNRAKMT2A | |
| SCHEMBL6073527 | 0.81 | CASP6 (0.60) | EDNRAKMT2A | |
| SCHEMBL23092875 | 0.81 | EDNRA (0.55) | NSD2EDNRAKMT2A | |
| SCHEMBL29900505 | 0.81 | EDNRA (0.55) | NSD2EDNRAKMT2A | |
| SCHEMBL3529089 | 0.80 | EDNRA (0.53) | EDNRAKMT2A | |
| SCHEMBL4446896 | 0.80 | CCR8 (0.64) | EDNRAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-117836270-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192562-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-10968172-B2 | USP30 inhibitors | MITOBRIDGE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968172-B2 | USP30 inhibitors | MITOBRIDGE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200131121-A1 | USP30 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-04-30 | — | — | US | disclosed |
| US-20200131121-A1 | USP30 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-04-30 | — | — | US | disclosed |
| WO-2018213150-A1 | USP30 INHIBITORS | MITOBRIDGE, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968172-B2 | USP30 inhibitors | USP30, UBQLN1, UBQLN2 | NSD2 1865/4885EDNRA 4422/4885USP30 1/4885 |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | NSD2 1033/4885EDNRA 4385/4885USP30 1/4885 |
| US-20200131121-A1 | USP30 INHIBITORS | USP30, UBQLN1, UBQLN2 | NSD2 1865/4885EDNRA 4422/4885USP30 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.